Analyst Price Target is $23.00
▲ +172.19% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Sangamo Therapeutics in the last 3 months. The average price target is $23.00, with a high forecast of $29.00 and a low forecast of $16.00. The average price target represents a 172.19% upside from the last price of $8.45.
Current Consensus is
The current consensus among 4 contributing investment analysts is to buy stock in Sangamo Therapeutics. This Buy consensus rating has held steady for over two years.
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.